Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

HORIZON THERAPEUTICS PUBLIC LIMITED COMPANY

(HZNP)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Horizon Therapeutics Public : Says New Data Backing Thyroid Eye Disease Drug Long-Term Efficacy; Shares Rise

10/21/2021 | 02:34pm EST


ę MT Newswires 2021
All news about HORIZON THERAPEUTICS PUBLIC LIMITED COMPANY
07:14aWells Fargo Starts Horizon Therapeutics at Overweight With $137 Price Target
MT
12/06INSIDER SELL : Horizon Therapeutics Public Ltd
MT
12/03Horizon Therapeutics plc Makes $100,000 Seed Donation to Support Fundraising Efforts to..
AQ
12/02Horizon Therapeutics plc Makes $100,000 Seed Donation to Support Fundraising Efforts to..
BU
12/02Great Place to Work Names Horizon Therapeutics plc to Best Workplaces for Parents List
BU
12/02INSIDER SELL : Horizon Therapeutics Public
MT
12/01Horizon Therapeutics plc Provides Academic Scholarships to Help Economically Disadvanta..
BU
11/22Horizon Therapeutics Says Phase 2/3 Data Support Efficacy of Uplizna in NMOSD Patients ..
MT
11/22New Analysis Published in Multiple Sclerosis and Related Disorders Supports the Efficac..
BU
11/22Horizon Therapeutics plc Announces That A New Post Hoc Analysis of the UPLIZNA N-Moment..
CI
More news
Analyst Recommendations on HORIZON THERAPEUTICS PUBLIC LIMITED COMPANY
More recommendations
Financials (USD)
Sales 2021 3 201 M - -
Net income 2021 583 M - -
Net Debt 2021 1 097 M - -
P/E ratio 2021 56,9x
Yield 2021 -
Capitalization 23 601 M 23 601 M -
EV / Sales 2021 7,72x
EV / Sales 2022 5,86x
Nbr of Employees 1 805
Free-Float 98,0%
Chart HORIZON THERAPEUTICS PUBLIC LIMITED COMPANY
Duration : Period :
Horizon Therapeutics Public Limited Company Technical Analysis Chart | HZNP | IE00BQPVQZ61 | MarketScreener
Technical analysis trends HORIZON THERAPEUTICS PUBLIC LIMITED COMPANY
Short TermMid-TermLong Term
TrendsBearishNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 12
Last Close Price 104,05 $
Average target price 142,42 $
Spread / Average Target 36,9%
EPS Revisions
Managers and Directors
Timothy P. Walbert Chairman, President & Chief Executive Officer
Paul W. Hoelscher Chief Financial Officer & Executive Vice President
Jeffrey W. Sherman Chief Medical Officer & Executive Vice President
Jeffrey D. Kent Executive VP-Medical Affairs & Outcomes Research
Karin Rosen Chief Scientific Officer
Sector and Competitors
1st jan.Capi. (M$)
HORIZON THERAPEUTICS PUBLIC LIMITED COMPANY39.49%23 145
JOHNSON & JOHNSON3.80%430 061
ROCHE HOLDING AG19.17%324 115
PFIZER, INC.39.85%290 297
NOVO NORDISK A/S70.26%250 392
ELI LILLY AND COMPANY45.17%222 215